CAMBRIDGE, Mass.–Platelet BioGenesis, Inc. announced that it has signed a lease for 18,000 square feet of lab space at 65 Grove Street in the emerging biotech hotbed of Watertown, Mass.
The space is being built-to-purpose to provide the physical infrastructure necessary for the company to scale its unique stem cell-derived platelet manufacturing platform, advance its core program to the clinic and establish proof of concept for platelet-based therapeutics.
“With a burgeoning life sciences ecosystem of its own, easy accessibility to the biotech cluster in Cambridge and high-quality space for reasonable rates, Watertown is an ideal location to establish PBG’s first stand-alone headquarters to support our ongoing growth,” said Sven Karlsson, co-founder, and chief operating officer of Platelet BioGenesis.
The announcement of the lease signing follows on the heels of other recent milestones for the rapidly advancing company, including naming a new President and CEO, Sam Rasty, Ph.D., and adding biotech industry veteran, Richard Murray, Ph.D., as a new independent board member.
Platelet BioGenesis has created the only platform that can generate human platelets at scale. The stem cell-derived, on-demand platelets will be the first donor-independent source of platelets to address the chronic shortage worldwide. The company is also developing platelet-based therapeutics, a new treatment modality for cancer and other life-threatening diseases. PBG’s platform is patented and cGMP-compliant.
